Moderna and Merck have reported promising results from a trial of more than 1,000 melanoma patients showing that their ...

An experimental new vaccine that could help prevent the deadly skin cancer melanoma from coming back after treatment is ...

Merck and Moderna say their personalized cancer vaccine reduced melanoma recurrence and spread in a Phase 3 trial.

The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short ...

Moderna’s cancer vaccine results doubled its stock price after taxpayers paid to help develop it.

Wall Street's major market averages traded in the red on Thursday, a day after equities moved higher after the U.S. Treasury ...

Tempus AI (TEM) stock surged 7% after BTIG raised its price target to $80 and Moderna's cancer trial win emphasized the value ...

Moderna stock soared 177% after a major cancer vaccine breakthrough. See Wall Street’s latest MRNA price targets and whether ...

Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of ...

Moderna shares jumped this week after the company announced encouraging results from a late-stage melanoma trial.

New mRNA vaccines and studies are demonstrating a flood of medical breakthroughs. But how much will the federal government stand in the way?